Psyence Biomedical Ltd.
NCM: PBMLive Quote
📈 ZcoreAI Score
Our AI model analyzes Psyence Biomedical Ltd.'s price action across multiple timeframes using regression channels and statistical scoring.
Get PBM Z-Score →About Psyence Biomedical Ltd.
Healthcare
Biotechnology
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder PTSD, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company has a strategic collaboration with PsyLabs to produce Ibogaine. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.
📊 Fundamental Analysis
Psyence Biomedical Ltd. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -74.3%, which indicates that capital utilization is currently under pressure.
At a current price of $2.67, PBM currently trades near the bottom of its 52-week range (0%), indicating potential value or weakness (Range: $1.92 - $468.36).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$6.12M
Trailing P/E
--
Forward P/E
--
Beta (5Y)
0.31
52W High
$468.36
52W Low
$1.92
Avg Volume
203K
Day High
Day Low